COLES N ANTHONY 4
4 · Cerevel Therapeutics Holdings, Inc. · Filed Jun 5, 2024
Insider Transaction Report
Form 4
COLES N ANTHONY
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2024-06-03$40.61/sh−50,000$2,030,520→ 15,638 total - Exercise/Conversion
Common Stock
2024-06-03$3.50/sh+50,000$175,000→ 65,638 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-06-03−50,000→ 2,202,417 totalExercise: $3.50Exp: 2028-12-24→ Common Stock (50,000 underlying)
Footnotes (3)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $40.29 to $40.89. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The option is fully vested and exercisable.